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Cryptosporidium parasites cause infection in
humans and other vertebrates, including
mammals, birds, reptiles, and fish. More than 20
species of Cryptosporidium have been reported,
of which six are considered valid species on the
basis of oocyst morphologic features and site of
infection (1,2). Cryptosporidium parvum, the
species that infects humans and most mammals,
has a monoxenous life cycle in which all stages of
asexual and sexual development occur within
one host. The parasite generates large numbers
of viable oocysts in feces. Cross-infection studies
in various mammalian systems have indicated
zoonotic transmission to humans (1,3). C. parvum
has caused waterborne outbreaks of cryptosporid-
iosis and (in AIDS patients) life-threatening
diarrhea for which no effective treatment exists
(4). A waterborne outbreak of cryptosporidiosis
in Milwaukee, Wisconsin, in 1993 affected more
than 400,000 people (5).
Molecular characterization techniques used
to detect intraspecific variations in C. parvum
include isozyme profiles (6); random amplified
polymorphic DNA (RAPD) analyses (7);
nucleotide sequence studies of the 18S rRNA
(8,9) and DHFR gene (10); and polymerase
chain reaction-restriction fragment length
polymorphism (PCR-RFLP) analysis of the
undefined repetitive sequence (11),
polythreonine motifs, and oocyst wall protein
(12,13). Two distinct genotypes of C. parvum
parasites have been detected in humans.
In a previous article, we identified several
mutations in the gene thrombospondin-related
anonymous protein 2 of C. parvum  (TRAP-C2)
that differentiate between anthroponotic and
zoonotic infection in humans (14). Our objective
in the present study was to develop a simple,
rapid protocol that can be used as a diagnostic
tool to differentiate between the two genotypes of
C. parvum and elucidate the transmission of
infection in humans. We analyzed 92 C. parvum
isolates from humans, calves, deer, dogs, and
monkeys and found that this new PCR/RFLP
method based on the TRAP-C2 gene sequence
can be used as a molecular marker to differentiate
between the two genotypes of C. parvum.
Analytic Approach
Isolates
We summarized data for 92 isolates of C.
parvum, 50 from human and 42 from animal
sources (Tables 1, 2). Twenty-one of the 50
human isolates were from AIDS patients; the
rest were primarily from cryptosporidiosis
outbreak case-patients. Seven of the human
isolates came from a previous TRAP-C2
sequencing study (14), but because of the lack
of DNA, other isolates we used in the previous
study were not used in this study. Fecal
samples were stored at 4° C in 2.5% potassium
dichromate before oocysts were isolated.
Oocysts were purified from fecal samples by
first using the discontinuous density sucrose
gradient centrifugation and then the Percoll
gradient centrifugation (15,16).
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Extraction of Genomic DNA and PCR
Amplification
We followed the protocol of Kim et al. in
isolating the total genomic DNA from the
purified oocyst (17). A 369 base pair (bp)
fragment of the TRAP-C2 gene of C. parvum was
amplified by using a forward (cua cua cua cua
CAT ATT CCC TGT CCC TTG AG) and a reverse
(cau cau cau cau TGG ACA ACC CAA ATG CAG
Table 1. Cryptosporidium parvum human isolates,
restriction pattern, and sequence type
Restric- Se-
tion quence
Source Isolate Host pattern type
1993 Milwaukee HM3 Huma Hum Humb
1993 Milwaukee HM5 Hum Hum Hum
1993 Milwaukee HM7 Hum Hum NDc
1995 Florida HFL1 Hum Hum Humb
1995 Florida HFL5 Hum Hum Humb
1995 Florida HFL6 Hum Hum ND
1995 Atlanta HGA1 Hum Hum Humb
1995 Atlanta HGA4 Hum Hum Hum
1995 Atlanta HGA5 Hum Hum ND
1995 Atlanta HGA6 Hum Hum ND
1996 Canada HCAN9 Hum Bovd Bovb
1995 Canada NC30 Hum Hum ND
1994 Nevada HCNV2 Hum Hum ND
1994 Nevada HCNV4 Hum Hum ND
1997 Pennsylvania PA41 Hum Bov Bovb
1997 Pennsylvania PA46 Hum Bov Bovb
1997 HIV-Guatemala HGMO7 Hum Hum Hum
1997 HIV-Guatemala HGMO8 Hum Hum ND
1997 HIV-Guatemala HGMO9 Hum Hum Hum
1997 HIV-Guatemala HGMO10 Hum Hum Hum
1997 Minnesota HMOB1 Hum Bov Hum
1997 Minnesota HMOB3 Hum Bov Bov
1997 Minnesota HMOB4 Hum Bov Bov
1997 Minnesota HMOB5 Hum Bov Bov
1997 HIV-New Orleans HNO2 Hum Hum Hum
1997 HIV-New Orleans HNO3 Hum Hum Hum
1997 HIV-New Orleans HNO4 Hum Hum ND
1997 HIV-New Orleans HNO5 Hum Bov Bov
1997 HIV-New Orleans HNO6 Hum Hum Hum
1997 HIV-New Orleans HNO7 Hum Hum Hum
1997 HIV-New Orleans HNO8 Hum Hum Hum
1997 HIV-New Orleans HNO10 Hum Hum Hum
1997 HIV-New Orleans HNO11 Hum Bov ND
1997 HIV-New Orleans HNO12 Hum Hum Hum
1997 HIV-New Orleans HNO13 Hum Hum Hum
1997 HIV-New Orleans HNO14 Hum Hum Hum
1997 HIV-New Orleans HNO15 Hum Hum Hum
1997 HIV-New Orleans HNO16 Hum Hum Hum
1997 HIV-New Orleans HNO17 Hum Hum Hum
1997 HIV-New Orleans HNO18 Hum Hum Hum
1997 HIV-New Orleans HNO19 Hum Hum ND
1997 India HIND4 Hum Hum Hum
1997 India HIND5 Hum Hum ND
1998 Washington State HWA1 Hum Hum Hum
1998 Washington State HWA2 Hum Hum ND
1998 Washington State HWA3 Hum Hum ND
1998 Washington State HWA4 Hum Hum ND
1998 Washington State HWA5 Hum Hum Hum
1998 Washington State HWA6 Hum Hum Hum
1998 Washington State HWA7 Hum Hum Hum
aHum=human
bSequencing data reported earlier (14)
cND= Not done.
dBov=bovine.
Table 2. Cryptosporidium parvum bovine isolates,
restriction pattern, and sequence type
Restric- Se-
tion quence
Source Isolate Host pattern type
1996 Alabama AAL35 Calf Bova Bov
1996 Georgia AGA43 Calf Bov Bov
1996 Georgia AGA44 Monb Bov Bov
1997 Georgia AGA75 Calf Bov Bov
1996 Idaho AID21 Calf Bov Bov
1996 Kansas AKA19 Calf Bov Bov
1996 Maryland AMD36 Calf Bov Bov
1996 Maryland AMD38 Deer Bov Bov
1996 Massachusetts AMA61- Calf Bov Bov
  GCH1
1997 Iowa AIO62 Calf Bov Bov
1996 Ohio AOH6 Calf Bov Bov
1996 Ohio AOH7 Calf Bov Bov
1996 Ohio AOH8 Calf Bov Bov
1996 Ohio AOH9 Calf Bov Bov
1996 Ohio AOH10 Calf Bov Bov
1996 Ohio AOH11 Calf Bov Bov
1996 Ohio AOH12 Calf Bov Bov
1996 Ohio AOH13 Calf Bov Bov
1996 Ohio AOH14 Calf Bov Bov
1996 Ohio AOH15 Calf Bov Bov
1996 Ohio AOH16 Calf Bov Bov
1996 Ohio AOH17 Calf Bov Bov
1997 Ohio AOH45 Calf Bov Bov
1997 Ohio AOH47 Calf Bov Bov
1997 Ohio AOH48 Calf Bov Bov
1997 Ohio AOH49 Calf Bov Bov
1997 Ohio AOH50 Calf Bov Bov
1997 Ohio AOH52 Calf Bov Bov
1997 Ohio AOH53 Calf Bov Bov
1997 Ohio AOH54 Calf Bov Bov
1997 Ohio AOH55 Calf Bov Bov
1997 Ohio AOH56 Calf Bov Bov
1997 Ohio AOH57 Calf Bov Bov
1997 Ohio AOH58 Calf Bov Bov
1997 Ohio AOH59 Calf Bov Bov
1997 Ohio AOH107 Dog Bov Bov
1996 Oklahoma AOK3 Beef Bov Bov
  cattle
1996 Oklahoma AOK29 Calf Bov Bov
1997 Pennsylvania APE89 Calf Bov Bov
1996 Utah AUT37 Calf Bov Bov
1996 Washington AWA5 Beef Bov Bov
 cattle
1997 West Virginia AWV65 Calf Bov Bov
aBov=bovine.
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AC) primer (lower case represents nucleotide
used for cloning); these primers correspond to
positions 848-867 (positive strand) and 1,180-
1,199 (negative strand) of the GenBank sequence
X77586, respectively. The PCR reaction con-
sisted of 50 ng genomic DNA, 200 mM of each
dNTP (Perkin Elmer, Foster City, CA), 40 ng of
primer, 1X PCR buffer, and 0.5 units of Taq
polymerase (GIBCO BRL, Frederick, MD) in a
total volume of 100 ml. DNA amplification was
carried out for 35 cycles, each consisting of
denaturing (94° C, 45 sec), annealing (48° C, 45
sec), and elongating (72° C, 60 sec), with an
initial hot start at 94° C for 5 min in a Perkin
Elmer Gene Amp PCR 9600 thermocycler. An
additional cycle of 7 min at 72° C was done for
final extension. Each experiment used three
negative controls (reaction mixtures without
Taq polymerase, primers, or template DNA)
and a positive control.
DNA Sequencing and Analysis
PCR products were purified by the Wizard
PCR Preps DNA purification system (Promega,
Madison, WI) and cloned by the CLONEAMP
pAMP1 System for Rapid Cloning of Amplifica-
tion Products (GIBCO BRL, Frederick, MD)
according to the manufacturers protocol. DNA
sequencing of recombinant clones that had the
correct size insert was carried out on an ABI 377
Automated Sequencer by the dRhodomine
Terminator Cycle Sequencing Kit (Perkin
Elmer-Applied Biosystems).
RFLP
To develop an RFLP technique for differenti-
ating between the two genotypes of C. parvum,
the TRAP-C2 sequences were aligned and
mapped for restriction enzyme sites by the
Genetics Computer Group program (18).
Enzymes with predicted exclusive cutting in
each genotype were used in RFLP development
and analysis. For RFLP analysis, 10 ml of
amplification products was digested in a 30-ml
reaction mix consisting of 10 units of BfaI (New
England BioLabs, Beverly, MA), BsetEI
(Boehringer Mannheim, Indianapolis, IN),
Eco571 (MBI Fermentas, Gariciuno, Vilnius,
Lithuania), HaeIII (New England BioLabs),
HphI (New England BioLabs), MaeIII (Boehringer
Mannheim, Germany), NruI (New England
BioLabs),  PacI (New England BioLabs), or Tsp45I
(New England BioLabs), and 3 ml of respective
restriction buffer for 1 hr, under conditions
recommended by the supplier. The digested
products were fractionated on 2.0% agarose gel
and visualized by ethidium bromide staining.
Findings
Sequence Analysis of Human and Bovine
Isolates
Two genotypes of C. parvum exist in
humans,  as shown by the primary sequence of
the TRAP-C2 gene (14). Nucleotide sequences
differed at five positions between most human
and bovine isolates. To confirm and extend this
observation, we sequenced additional human
and bovine isolates, as well as isolates from dogs,
deer, and monkeys. We obtained 42 additional
sequences of the TRAP-C2 gene from animal
sources and 27 additional sequences of the
TRAP-C2 gene from human sources; results of
DNA sequencing confirmed that C. parvum is
highly conserved at the TRAP-C2 locus. All
animal isolates, including those from nonbovine
animals, showed bovine genotype characteristics
(Table 2). Differences between the two genotypes
are shown in Table 3. Of the additional 23 human
isolates showing human genotype pattern, four
isolates (HGMO7, HGMO9, HGMO10, and
HNO18) showed C at the fifth place, whereas
the rest showed T.
PCR-RFLP Method To Discriminate between
Human and Bovine Genotype Isolates
To avoid expensive and lengthy DNA
sequencing when determining the genotype of
C. parvum isolates, we developed a simpler,
quicker  methodPCR amplification of the
TRAP-C2 gene followed by RFLP. Restriction
Table 3. Human and bovine Cryptosporidium parvum
isolates based on multiple alignmenta
Position (nt) Human genotype Bovine genotype
  51 G A
  78 C T
100 T G
147 C T
280 T or C C
aRepresentative sequences have been deposited in the
GenBank, with accession numbers AF082521 to AF082524.684 Emerging Infectious Diseases Vol. 4, No. 4, OctoberDecember 1998
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enzyme mapping on the aligned sequences of
both genotypes showed five human-genotype
specific (HaeI, HaeIII, NruI, PacI, and ThaI) and
six bovine-genotypespecific (BfaI, BsetEI,
Eco571,  HphI,  MaeIII, and Tsp45I) restriction
enzymes. All human-genotype and bovine-
genotypespecific restriction enzymes except
HaeI and ThaI were tested for the TRAPC-2
PCR-amplified products of genomic DNA of
C. parvum. After restriction and gel
electrophoresis, the resulting bands were
the size predicted by the mapping analysis
(Figure). Digestion of PCR products with these
enzymes resulted in a distinct band pattern for
the human genotype and bovine genotype
isolates. In all cases, the DNA sequencing and
PCR-RFLP mapping data matched.
Using PCR-RFLP in Outbreak Investigations
We validated the PCR-RFLP technique by
using isolates from outbreaks and sporadic cases
of human cryptosporidiosis. Human genotype
characteristics were evident in all samples from
HIV-infected patients from Guatemala and most
patients with sporadic clinical cases, as well as
samples from the following outbreaks: Milwau-
kee (1993), Florida (1995), Atlanta (1995),
Canada (1995), Nevada (1994), and Washington
(1998). Of the 17 samples from HIV-infected
patients in New Orleans, two demonstrated
bovine-genotype pattern, while the rest were
similar to human genotype. However, bovine-
genotype characteristics were evident in the
human isolates from outbreaks in British
Columbia, Canada (1996), Minnesota (1997), and
Pennsylvania (1997).
Conclusions
We examined a large number of C. parvum
isolates (92) from human and animal sources
from patients in outbreak and nonoutbreak
settings to determine the two transmission
routes of the parasite in humans. Molecular
markers were generated by restriction digestion
of PCR-amplified TRAP-C2 products with one of
the 12 enzymes to differentiate the two
genotypes of C. parvum. The results based on
TRAP-C2 gene PCR-RFLP showed that this
method could also be used in future
cryptosporidiosis outbreak investigations.
Results of our characterization of outbreak
and nonoutbreak cases of human cryptosporidiosis
indicate that anthroponotic organisms account
for most cases. We find a large number of human
genotype parasites in sporadic cases and in HIV-
infected patients. Most cryptosporidiosis out-
breaks examined are caused by anthroponotic
(human genotype) parasites. Our results suggest
similar epidemiologic features of cryptosporidiosis
in HIV-infected persons from New Orleans and
Guatemala because both were infected with
human genotype parasites.
The results of this study confirm the
polymorphic nature of C. parvum. As we showed
in a previous study, two alleles of the TRAP-C2
gene exist, each representing a distinct genotype
of C. parvum with different transmission cycles
in humans. The simple PCR-RFLP technique we
developed can effectively differentiate between
these two genotypes and transmission cycles and
can be used as a tool in outbreak investigations of
cryptosporidiosis. Information generated from
these investigations will be useful not only in
Figure. Human- and bovine-specific restriction
enzymes showed distinct banding pattern for
genotypes of Cryptosporidium parvum isolates. The
different lanes represent the TRAP-C2 PCR-
amplified products belonging to AGA43, AMD36,
AOH6, HM3, and HM5 isolates of C. parvum,
respectively, after digestion with HaeIII (Lanes 1-5,
human-specific marker) and BstE II (Lanes 7-11,
bovine-specific marker) restriction enzymes and
agarose gel electrophoresis. Lane 6 is the 100 bp
marker. Samples AGA43, AMD36 and AOH6 are
bovine (bovine genotype) and samples HM3 and HM5
are human (human genotype). Human- or bovine-
specific restriction enzyme markers can cut only the
TRAP-C2 amplified product of the respective
genotype of C. parvum isolates.685 Vol. 4, No. 4, OctoberDecember 1998 Emerging Infectious Diseases
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identifying the sources of contamination but also
in controlling the disease.
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